Physician profile
Daniel L Kulick
NPI 1679550123
$2,605.99
in general payments reported to CMS, 2019-2025
28 companies · $424 in 2025
The $424 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $725 · 2020: $236 · 2021: $187 · 2022: $149 · 2023: $244 · 2024: $641 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,308.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $372.25 | 2019-2023 | Repatha |
| Abbott Laboratories | $344.25 | 2019-2025 | Xience Skypoint, Ensite, Dragonfly Opstar |
| Cvrx, INC. | $291.99 | 2024-2025 | Barostim Neo System |
| Chiesi USA, INC. | $246.09 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $179.10 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $120.85 | 2019-2024 | Avvigo Guidance System, Lux-Dx Insertable Cardiac Monitor, Watchman Flx |
| Biotronik INC. | $109.09 | 2020 | |
| Medtronic, INC. | $88.77 | 2025 | Onyx Frontier |
| Angiodynamics, INC. | $86.53 | 2023 | Venacure 1470 Pro |
| Cardiovascular Systems INC. | $77.82 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $69.41 | 2023-2024 | Amvuttra |
| Shockwave Medical, INC | $64.48 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $62.91 | 2024-2025 | Lifevest |
| Astellas Pharma US INC | $62.12 | 2019 | |
| Scpharmaceuticals INC. | $48.51 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $44.93 | 2019-2022 | |
| Kestra Medical Technology Services, INC. | $39.72 | 2022-2025 | Assure Wcd |
| Astrazeneca Pharmaceuticals LP | $39.05 | 2020 | |
| Medtronic Vascular, INC. | $35.26 | 2019 | |
| Novartis Pharmaceuticals Corporation | $33.56 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.29 | 2023-2024 | Jardiance |
| Impulse Dynamics (USA) INC. | $25.94 | 2025 | Optimizer |
| Regeneron Healthcare Solutions, INC. | $25.47 | 2024 | Evkeeza |
| Acist Medical Systems, INC. | $25.06 | 2024 | |
| Novo Nordisk INC | $23.97 | 2025 | Wegovy |
| Cathworks, INC. | $21.29 | 2019 | |
| Merck Sharp & Dohme LLC | $18.57 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kulick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.